World Journal of
Pharmaceutical and Life Sciences

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Life Sciences
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
World Journal of Pharmaceutical and Life Sciences (WJPLS) has indexed with various reputed international bodies like : Google Scholar, Index Copernicus, Scientific Indexing Services (SIS), Indian citation Index (ICI), Directory of Research Journals Indexing, Scintific journal impact factorScientific Journal Impact Factor (SJIF), Jour Informatics (Under Process), UDLedge Science Citation Index, Global Impact Factor (In Process), International Impact Factor Services, International Society for Research Activity (ISRA) Journal Impact Factor (JIF), Science Library Index, Dubai, United Arab Emirates, International Innovative Journal Impact Factor (IIJIF), Scientific Journal Impact Factor (SJIF), Eurasian Scientific Journal Index (ESJI), Cosmos Impact Factor, IFSIJ Measure of Journal Quality, International Scientific Indexing, UAE (ISI), Web of Science Group (Under Process), Research Bible, Fuchu, Tokyo. JAPAN, Scholar Article Journal Index (SAJI), Scope Database, Academia, 



Ponnu Sarah Joseph, Jasmin Jomon, Shary Ramesh, Devi K R and Nithin Manohar*


Antibodies are natural proteins with modular structure, specific pharmacodynamics and pharmacokinetics and possibly produced against any antigens, thus giving them several advantages over small drug therapeutics. Monoclonal antibodies (mAb) have been applied to the diagnosis and therapy of an array of human diseases. They are a novel and promising therapeutic class used with great results in inflammatory diseases such as rheumatoid arthritis. The initial failures of early clinical trials have been overcome through the production of a new generation of mAb which features reduced immunogenicity and improved targeting abilities. The early models of mAb therapy were focused on enhancing the cytolytic mechanisms against the tumor cells. More recently, successful mAb-based therapies were targeted to molecules involved in the regulation of growth of cancer cells. Despite all the difficulties, clinical data is outlining an increasingly significant role for antibody-mediated cancer therapy as a versatile and powerful instrument in cancer treatment. Lung cancer is the leading cause of cancer-related deaths in industrialized countries and non small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. It seems that mAbs therapy in NSCLC clearly marks the start of a new era in NSCLC treatment, with promise in improving patient survival and quality of life. Monoclonal antibodies (MAbs) are an old immunological tool with applications in the fields of immunology, biotechnology, biochemistry, and applied biology. Recently, MAbs have been widely applied in the field of clinical medicine. Currently, MAbs account for one-third of all the new therapeutic treatments for breast cancer, leukemia, arthritis, transplant rejection, asthma, and psoriasis, with many more late-stage clinical trials being conducted. In this review, we outline the (i) production of MAbs, (ii) application of MAbs, (iii) antibody engineering, and (iv) pharmaceutical application of MAbs.

[Full Text Article]   [Download Certificate]


  All Since 2019
 Citation  422  322
 h-index  9  7
 i10-index  4  2



    A PHP Error was encountered

    Severity: Notice

    Message: Undefined variable: news

    Filename: views/right_panel.php

    Line Number: 79

    A PHP Error was encountered

    Severity: Warning

    Message: Invalid argument supplied for foreach()

    Filename: views/right_panel.php

    Line Number: 79


World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .

Best Article of current issue

Download Article : Click here